Psoriasis is a chronic skin condition that significantly impacts the physical and mental well-being of those affected. The standard treatment approach involves the local application of pharmaceutical preparations to alleviate symptoms, but achieving effective skin permeation and targeting remains a challenge due to the skin's formidable barrier properties. This study introduces a novel carrier material derived from mussel adhesive protein (MAP)-functionalized Pluronic F127, designed to enhance the cutaneous absorption of curcumin (Cur) and improve topical therapeutic efficacy in psoriasis. The MAP-F127/Cur micelles were characterized and their skin permeation, retention, and therapeutic effects were evaluated in vitro and in vivo.
The MAP-F127/Cur system demonstrated superior skin retention compared to conventional nanocarriers, achieving a retention approximately 5 times greater than Cur solutions. This enhanced drug availability within the skin is advantageous for obtaining potent and prolonged pharmacological effects. The micelles also exhibited improved skin permeation via the stratum corneum (SC), hair follicles, and other skin appendage pathways. In vivo studies showed that MAP-F127/Cur significantly alleviated both the symptoms and histopathological manifestations in imiquimod (IMQ)-induced psoriasis-like mice, confirming its potential as a promising topical treatment for psoriasis.
But here's where it gets controversial: the MAP-F127/Cur formulation's therapeutic effect was still inferior to that of the positive control drug, clobetasol propionate (CP). This difference primarily stems from CP's potent action as a super-high-potency glucocorticoid, but long-term use carries the risk of adverse effects like skin atrophy. The MAP-F127/Cur system, however, holds promise as a safer therapeutic alternative. This raises an important question: should we prioritize the safety of patients or the potency of the treatment? What are your thoughts on this trade-off? Share your opinions in the comments below!
